Literature DB >> 24361427

Improving protein delivery of fibroblast growth factor-2 from bacterial inclusion bodies used as cell culture substrates.

Joaquin Seras-Franzoso1, Karl Peebo2, Elena García-Fruitós3, Esther Vázquez3, Ursula Rinas4, Antonio Villaverde3.   

Abstract

Bacterial inclusion bodies (IBs) have recently been used to generate biocompatible cell culture interfaces, with diverse effects on cultured cells such as cell adhesion enhancement, stimulation of cell growth or induction of mesenchymal stem cell differentiation. Additionally, novel applications of IBs as sustained protein delivery systems with potential applications in regenerative medicine have been successfully explored. In this scenario, with IBs gaining significance in the biomedical field, the fine tuning of this functional biomaterial is crucial. In this work, the effect of temperature on fibroblast growth factor-2 (FGF-2) IB production and performance has been evaluated. FGF-2 was overexpressed in Escherichia coli at 25 and 37 °C, producing IBs with differences in size, particle structure and biological activity. Cell culture topographies made with FGF-2 IBs biofabricated at 25 °C showed higher levels of biological activity as well as a looser supramolecular structure, enabling a higher protein release from the particles. In addition, the controlled use of FGF-2 protein particles enabled the generation of functional topographies with multiple biological activities being effective on diverse cell types.
Copyright © 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug delivery; Inclusion bodies; Nanomedicine; Protein release; Surface functionalization

Mesh:

Substances:

Year:  2013        PMID: 24361427     DOI: 10.1016/j.actbio.2013.12.021

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  6 in total

1.  Purification of Inclusion Bodies Produced in Bacteria and Yeast.

Authors:  Joaquin Seras-Franzoso; Olivia Cano-Garrido; Spela Peternel; Anna Arís; Elena Garcia-Fruitós
Journal:  Methods Mol Biol       Date:  2022

2.  Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs.

Authors:  María Virtudes Céspedes; Yolanda Fernández; Ugutz Unzueta; Rosa Mendoza; Joaquin Seras-Franzoso; Alejando Sánchez-Chardi; Patricia Álamo; Verónica Toledo-Rubio; Neus Ferrer-Miralles; Esther Vázquez; Simó Schwartz; Ibane Abasolo; José Luis Corchero; Ramon Mangues; Antonio Villaverde
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

3.  Positive in vitro wound healing effects of functional inclusion bodies of a lipoxygenase from the Mexican axolotl.

Authors:  Anne Stamm; Sarah Strauß; Peter Vogt; Thomas Scheper; Iliyana Pepelanova
Journal:  Microb Cell Fact       Date:  2018-04-07       Impact factor: 5.328

4.  A new generation of recombinant polypeptides combines multiple protein domains for effective antimicrobial activity.

Authors:  Ramon Roca-Pinilla; Adrià López-Cano; Cristina Saubi; Elena Garcia-Fruitós; Anna Arís
Journal:  Microb Cell Fact       Date:  2020-06-05       Impact factor: 5.328

5.  Influence of pH control in the formation of inclusion bodies during production of recombinant sphingomyelinase-D in Escherichia coli.

Authors:  Andrea Castellanos-Mendoza; Ricardo M Castro-Acosta; Alejandro Olvera; Guadalupe Zavala; Miguel Mendoza-Vera; Enrique García-Hernández; Alejandro Alagón; Mauricio A Trujillo-Roldán; Norma A Valdez-Cruz
Journal:  Microb Cell Fact       Date:  2014-09-12       Impact factor: 5.328

6.  Recombinant Protein-Based Nanoparticles: Elucidating their Inflammatory Effects In Vivo and their Potential as a New Therapeutic Format.

Authors:  Laia Gifre-Renom; Estefania Ugarte-Berzal; Erik Martens; Lise Boon; Olivia Cano-Garrido; Esther Martínez-Núñez; Teresa Luque; Ramon Roca-Pinilla; Òscar Conchillo-Solé; Neus Ferrer-Miralles; Antonio Villaverde; Ghislain Opdenakker; Elena Garcia-Fruitós; Anna Arís
Journal:  Pharmaceutics       Date:  2020-05-13       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.